As a result of significant public research and development investment, many promising prototypes for nanomedicine applications in the areas of therapeutics, diagnostics and regenerative medicine are reaching clinical trials and are entering the regulatory approval pathway.
There is a growing requirement by regulators and developers, to de-risk translation by better understanding the critical determinants of efficacy and safety. Nanotechnology offers great promise for treatment and diagnostics but is constrained by expertise required for robust characterisation needed for progression towards clinical trials.
Led by The Nanotherapeutics Hub located at the University of Liverpool, this platform provides industry partners access to the Hub’s expertise and its network of UK partner organisations to support the development of innovative new antimicrobials, and vaccines, leveraging nanotechnology.
For more information or to learn how your business can engage with this platform.
Lecturer of Pharmacology at the University of Liverpool, Coordinator of The Nanotherapeutics Hub at The University of Liverpool
Dr Liptrott has a background in pharmacology, immunology, immunopharmacology and molecular cell biology. His research is aimed at investigating the biological interactions of conventional and nanotechnology-enabled medicines and therapeutics as well as other novel therapeutic strategies such as cellular therapies.